T enascin-C is a large h exam eric extracellu lar m atrix glycoprotein that is expressed in a tem p o ra lly and spatially restricted pattern associated w ith stro m a lepithelial in teraction s. In adult h u m an skin, th e e x pression level o f ten a scin -C Is lo w , b u t ten a scin -C is abundantly present in the derm al co m p a rtm en t dur in g em bryogenesis and w o u n d h e a lin g and in skin tum ors. H erein w e have in v e stig a te d the cellu lar source o f tenascin-C p ro d u ctio n in h u m an skin, b oth in vivo and in vitro, by u sin g im m u n o h is to ch em istry, m R N A in situ h yb rid ization , w estern b lo ttin g , and an en zym e-lin ked im m u n o so rb en t assay. In a d d itio n w e studied the cell-m a trix in tera ctio n b e tw e e n ep id er m al keratinocytes and pu rified ten a scin -C . B y u sin g in vitro culture m o d els, w e fo u n d th at k era tin o cy tes n o t only syn th esize and secrete ten a scin -C b u t can also deposit ten ascin -C in d e-ep id erm ized derm is in a pattern that is very sim ilar to that in vivo. In vivo" during w ou n d h ea lin g o f norm al hum an skin, we fou n d tenascin-C extracellularly in the w ound bed and also in a granular pattern w ithin the neo-epider m is. B y m R N A in situ hybridization, w e could identify the basal m igrated keratinocytes as the m ain source o f tenascin-C in th e early phase o f w ound healing. In the granulation phase, tenascin-C expression by the k eratin ocytes is dow nregulated. Cultured keratino cytes w ere fou n d to adhere poorly to tenascin-C , and th o se that did adhere retained a rounded m orphol ogy-W e co n clu d e that hum an keratinocytes are a m ajor source o f ten ascin -C during the early phase o f w ou n d h ealin g, and w e hypothesize that tenascin-C is u n lik ely to be an adhesive substrate for m igrating k eratin ocytes. Key tvords: in situ hybridization/epitheli um! cell adhesion. J Invest Dermatol 108: [776] [777] [778] [779] [780] [781] [782] [783] 1997 T enascin-C is a large hexameric extracellular matrix glycoprotein consisting o f subunits o f 220-320 kDa that are linked by disulfide bonds (for review see Schenk and Chiquet Ehrismann, 1994; Chiquet Ehrismann et al, 1994; and Lightner, 1994) . The tenascin-C subunits have a m odular structure, in liumans forming a cysteine-rich domain at the N terminus, followed by 14-5 domains with homology to epidermal grow th factor, a num ber of fibronectin type III repeats (varying from 9 to 16 as a result o f alternative splicing of tenascin-C R N A ), and a fibrinogen-like domain at the C terminus. Recently, two proteins with the same general structure have been described, named tenascin-R (or restrictin) and tenascin-X. In analogy, tenascin is called tenascin-C in more recent literature, where the C stands for cytotactin, a synonym for tenascin.
Teuascin-C is abundant during embryogenesis, particularly at mcsenchymal-epithelial interaction sites (Crossin et al, 1986;  detected in the dermis, where it is sparsely distributed at the dermal-epidermal junction and surrounds blood vessels and epi dermal adnexa (Lightner et al, 1989; Schalkwijk et al, 1991b; Shikata et al, 1994) . In conditions of epidermal hyper-proliferation, such as psoriasis (Schalkwijk et al, 1991b) , epidermal tumors (Stamp, 1989; Schalkwijk et al, 1991b; Verstraeten et al, 1992; Shikata et al, 1994) , and injury (Schalkwijk et al, 1991a; Betz et al, 1993; Juhasz et al, 1993; Latijnhouwers et al, 1996) , tenascin-C expression in the papillary dermis is strongly upregulated. The role o f tenascin-C in vivo is still a matter of debate. In vitro studies have suggested various functions for tenascin-C, including modulation o f cell proliferation and cell adhesion Friedlander et al, 1988; Lotz et al, 1989; Spring et al, 1989; Lightner and Erickson, 1990; M urphy Ullrich et al, 1991; Prieto et al, 1992 Prieto et al, , 1993 and suppression o f the immune response (Ruegg et al, 1989; Hemesath et al, 1994) . Knocking out the tenascin-C gene in mice, however, does not induce marked phenotypic changes, W h eth er the tenascin-C-like molecules tenascin-R and tenascin-X in these knock-out mice take over the functions that are normally exhibited by tenascin-C is not yet clear.
For many tissues, reports pointed to mesenchymal cells as the cellular source of tenascin-C, whereas epithelial cells induce or modulate tenascin-C production. W hen mesenchyme is co-cul ture d w ith epithelial cells, for example, mesenchymal tenascin-C expression is induced (Aufderheide and Ekblom, 1988; Inaguma et al, 1988) . In vivo, increase in mesenchymal tenascin-C also corre lates with epithelial changes, notably epidermal hyper-proliferation in skin (Stamp, 1989; Schalkwijk et ai, 1991a Schalkwijk et ai, , 1991b Betz et al, 1993; Juhasz et al, 1993; Shikata et al, 1994; Latijnhouwers et al, 1996) . Consequently, epidermal keratinocytes were considered to merely stimulate tenascin-C production of dermal fibroblasts in skin. More recently, how ever, epithelial cells were reported to produce tenascin-C as well. Cells may secrete tenascin-C only when cultured in vitro (Kawakatsu et al, 1992) and not after injection in nude mice (Sakai et al, 1993) , although the opposite is possible as well (Hiraiwa et al, 1993) . Immunohistochemically, tenascin-C was detected in developing corneal epithe lium (Kaplony et al, 1991) , epithelial lung tum or cells (Soini et al, 1993) , human amnion cells (Linnala et al, 1993) , and hum an breast tissue (Lightner et al, 1994) . It should be noted, how ever, that the extracellular localization of tenascin-C hampers the immunohistochemical identification of cells expressing tenascin-C. In situ hy bridization is the preferred approach to identify the cellular source o f tenascin-C. By in situ hybridization, tenascin-C m R N A was detected in the epithelium of developing bronchi (Prieto et al, 1990; K och et al, 1991) in normal and malignant breast epithelium {Lightner et al, 1994) and cornea (Tucker, 1991) . In the epithelium o f developing chicken feather buds, however, no tenascin-C m R N A was found (Prieto et alf 1990) . These findings o f epithelial tenascin-C expression led us to further examine tenascin-C expres sion in skin. Our data demonstrate that epidermal keratinocytes secrete tenascin-C and deposit tenascin-C in the extracellular m atrix in vitro and in vivo during wound healing. In addition we investigated the effect of tenascin-C in cell adhesion assays. The results indicate that tenascin-C is a poor adhesive substrate for cultured keratinocytes.
MATERIALS AND METHODS C ells a n d C ulture C o n d itio n s Tcnascin-C production was examined in hum an glioblastoma and osteosarcoma cell lines and in primary cultures of epidermal keratinocytes and dermal fibroblasts. The hum an glioblastoma cell lines U87-MG, U138-MG, and U373-MG were provided by R. Verstraeten (Free University of Amsterdam, The Netherlands), and Saos-2 sarcoma cells were a gift from E. Mackie (Royal Veterinary College, London, United Kingdom). The cel] lines are available from the American Type Culture Collection (Rockville, MD) asHTB14, HTB16, HTB17, and H TB 85, respectively. All cultured cells were tested negative for myco plasma.
Cell lines and dermal fibroblasts were grown in D ulbecco's modified Eagle's medium (DMEM)/F-12, 3:1 (vol/vol), supplemented with penicil lin (100 units per ml) plus streptomycin (100 jitg per ml) and 10% fetal bovine serum. Human keratinocytes from skin biopsies o f healthy donors were initially cultured by the method of Rheinwald and Green (1975) . Keratinocytes from these cultures were again seeded on a feeder layer of irradiated 3T3 cells or, alternatively, in serum-free medium. For the method o f Rheinwald and Green, DMEM/F-12, 3:1 (vol/vol), supplemented with 0.4 |U.g hydrocortisone per ml, 1 jU,M isoproterenol, 10 ng epidermal growth factor per ml, 6% fetal bovine serum, 100 units penicillin per ml, and 100 jug streptomycin per ml was used. Serum-free culture medium was keratinocyte grow th medium (KGM). KGM was composed o f keratinocyte basal me dium (Clonetics, San Diego, CA; 0.15 mM calcium) supplemented with 0.1 m M ethanol amine, 0.1 M phosphoethanolamine, 10 ng epidermal growth factor per ml, 5 (ig insulin per ml, 0.4% (vol/vol) bovine pituitary extract (Clonetics, San Diego, CA), 0.5 ¡xg hydrocortisone per ml, 100 units penicillin per ml, and 100 fig streptomycin per ml.
Before reaching confluency, the serum concentration o f serum-containing m edium was lowered to 1%. After 3 d, medium was collected and te n a s c in -C concentrations were determined by an enzyme-linked immu nosorbent assay (ELISA).
I n V itro R e c o n stru c tio n o f Epiderm is on D e -E p id e rm iz e d D erm is (D E D ) Keratinocytes cultured by the method o f Rheinwald and Green w ere seeded on DED and cultured in DMEM/F-12, 3:1 (vol/vol), supple m ented with 5% HyClone newborn bovine serum (Greiner, Alphen a/d Rijn, T he Netherlands), 0.4 /¿-g hydrocortisone per ml, 1 /xM isoproterenol, and 5 ju,g insulin per ml. Cultures were maintained submerged in the m edium for 3 d and then were air-exposed for another 3-14 d. The medium used for air-exposed culture was supplemented with 10 ng epidermal grow th factor per ml. Generation of DED and culture methods have been described previously (Prunieras et al, 1983; Ponec, 1991) . B io p sie s Experimental wounds were made by taking partial thickness punch biopsies with a diameter of 3 mm from the upper arm o f healthy volunteers. Full-thickness punch biopsies with a diameter o f 4 mm were taken from the different wounds after 2, 4, 7, 14, 60, and 365 d, These secondary biopsies, which included the healing wounds and some of the adjacent normal skin, were embedded in Tissue T ek OTC compound and stored at ~80°C until use or were formalin-fixed and embedded in paraffin. Permission for experiments on humans was obtained from the Medical Ethical Committee of the University Hospital in Nijmegen.
A n tise ru m Antibodies directed against hum an tenascin-C were the mouse monoclonal antibodies T2H 5 (for reference, see Schalkwijk et al, 1991a) and TN 2 (Dako, Glostrup, Denmark) and two rabbit polyclonal antiserums A107 and TN953. A107 was obtained from Chcmicon Interna tional (Temecula, CA). W e raised TN953 in N ew Zealand White rabbits by immunization with highly purified hum an tenascin-C from U138-MG cells. Traces of anti-fibronectin reactivity in TN953 were removed by solid-phase absorption with human fibronectin. Antibodies against human fibronectin were a mouse monoclonal antibody (Sigma-Aldrich, Bornem, Belgium) and a rabbit polyclonal antiserum (Life Technologies, Breda, The Netherlands).
Im m u n o h is to c h e m istry T2H 5, TN 2, and TN953 were used for stain ing of tenascin-C in cryostaf sections. In addition, TN 2, TN953, and A107 were applied to detect tenascin-C in formalin-fixed sections. Staining with T2H5 was performed by an indirect imimmoperoxidase staining protocol described previously that uses 3-amitio-9-ethylcarbazole as a chromogenic substrate (Schalkwijk ct al, 1991a) . For TN 2, TN953, and A107, the Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA) was used according to the manufacturer's instructions, with diaminobenzidine as a chromogenic substrate, After immunostiiining, sections were counterstained with hematoxylin.
ELISA To quantify tenascin-C concentrations in culture medium, a sandwich-type ELISA was developed that is similar to the one described by Schenk and colleagues (1995) . Polystyrene microtiter plates were coated with T2H5. After blocking free protein binding sites with bovine serum albumin (BSA), dilution series o f samples, standard, and blanks were incubated in the wells, and A107 was subsequently used to detect bound tenascin-C. A107 binding was assessed with peroxidase-conjugated swine anti-rabbit immunoglobulins and o-phenylene diamine dihydro chloride as the chromogenic substrate. The color reaction was stopped by adding 4 M H 2SO.( and evaluated by reading the absorption of the color product at 490 nm, with 655 nm as a reference wavelength. The same method was applied for the fibronectin-specific ELISA. For these a mouse monoclonal antibody and a rabbit polyclonal antiserum against human fibronectin were used. Chicken egg ovalbumin was used instead of BSA in the fibronectin ELISA.
The standards used in ELISAs were hum an tenascin-C purified from the melanoma cell line SK-MEL-28 by L. Zardi (Instituto Nazionale per la Ricerca sul Cancro, Genoa, Italy) and fibronectin from human plasma (0.1% solution, Sigma-Aldrich, Bomem, Belgium). The detection limits were approximately 20 ng tenascin-C per ml or 80 ng fibronectin per ml, respectively.
C o n stru c tio n o f P la sm id s a n d S y n th esis o f R N A Probes Total R N A was isolated from cultured human dermal fibroblasts, and cDNA was synthesized by reverse transcription with oligo(dT) primers. Part of the cDNA was amplified by using a polymerase chain reaction and subcloned in pGEM-3. The tenascin-C-coding insert corresponds to nucleotides 6016-6475 of the hum an tenascin-C cDNA sequence as submitted by Gherzi and colleagues to the EMBL Database Library (accession number X78565), spanning part o f the most C-terminally located fibronectin type III repeat and part of the fibrinogen-like domain.
The plasmid was linearized with B autH I to synthesize an anti-sense complementary R N A probe by using T7 polymerase and with EcoRI to synthesize control sense complementary R N A by using Sp6 polymerase in the reverse orientation. Dioxigenin (DIG)-labeled anti-sense and sense probes were synthesized by using a Sp6/T7 in vitro R N A synthesis lot in the presence o f D IG -U TP (Boehringer Mannheim, Mannheim, Germany). Synthesis was performed at 37°C with T7 polymerase and at 40°C with Sp6 polymerase. The anti-sense probe thus produced was 471 nucleotides long, and the sense probe was 498 nucleotides long.
In S itu H y b rid iz a tio n In situ hybridization was performed on frozen sections as described (Pfundt et 1996) with the modification that the 0.1X sodium citrate/chloride buffer used to wash slides after hybridization contained 60% form amide instead of 50%. Optimal probe concentrations were determined in a pilot experiment: 200 ng per ml was choosen for further use. Hybridization was assessed with Fab fragments of sheep anti-DIG monoclonal antibodies conjugated to alkaline phosphatase (Boehringer Mannheim) and subsequent staining with nitro blue tetrazolium and 5-bromo-4-chloro-4-indolyl phosphate.
T en ascin -C P u rific a tio n U138-M G was used for tenascin-C purifica tion. Before the cells reached confluency, the serum concentration of the medium was lowered to 1 % fetal bovine serum and cultures were maintained for an additional 2 mo, during which medium was collected every 3 or 4 d for tenascin-C purification. Proteinase inhibitors (2 m M ethylenediamine tetraacetic acid, 0.3 mM phenylmethylsulfonyl fluoride, and 2 fig aprotinin per ml) and 0.05% N aN 3 were added to the collected medium. The medmm was subjected to two rounds o f anion-exchange chromatog raphy. First, tenascin-C was eluted from hydroxyl apatite in a batchwise manner with increasing concentrations of N a2H P 0 40*12H20 . The fractions that contained most o f the tcnascin-C were used for final purification on the Smart System using a Mono Q HR. 5/5 column (Pharmacia, Uppsala, Sweden) and a gradient of 0.1-1 M N aC l in 20 m M Tris(hydroxymethyl) aminomethane (pH 7.9). In this way, tenascin-C could be quantitatively separated from fibronectin (see F ig 6). The concentration o f purified tenascin-C was quantified by ELISA. Qualitative analysis included fibronectin specific ELISA and western blotting, In addition, the hemagglutinating activity of the tenascin-C preparations was verified (Erickson and Inglesias, 1984; Chiquet Ehrismann et al, 1986) . O n western blots of reduced tenascin-C, specific antiserum stained two tenascin-C bands with molccular weights exceeding 200 kDa. The only contaminating proteins were traces of fibronectin and BSA; laminin was not detected. According to ELISA results, the purified tenascin-C typically contained less than 3% fibronectin.
Cell A dhesion Assays Adhesive proteins used in the adhesion assays were fibronectin from human plasma (Q.1% solution, Sigma-Aldrich, Borncm, Belgium), laminin purified from human placenta (Life Technolo gies, Breda, The Netherlands), tenascin-C purified from the glioblastoma cell line U251-MG (Chemicon International, Temecula, CA)> and human tenascin-C that we purified ourselves from the glioblastoma cell line U138-MG. Polystyrene microtiter plates were coated by incubation over night at 4°C with 50 (jl\ o f a solution containing the appropriate protein diluted in Dulbecco's PBS (DPBS -PBS containing 0.9 m M C aC l2 • 2H20 and 0.49 mM MgCI2 * 6H 20 ). U nbound protein was removed by washing with DPBS and free protein binding sites w ere blocked by incubation for 1 h at 37°C with DPBS containing 1 % BSA.
For adhesion assays only secondary cultures of keratinocytes were used. Cells from subconfluent keratinocyte cultures were harvested by trypsinization and subsequently resuspended ill DPBS with 5% fetal calf serum to inactivate trypsin. In cases where keratinocytes had been cultured according to the method of Rheinwald and Green, the feeder cells were rem oved witli ethylenediamine tetraacetic acid prior to trypsinization. After two washes in succession with DPBS and DMEM supplemented with 0.25% BSA and 20 mM HEPES (pH 7.4), cells were resuspended in DMEM, 0.25% BSA, and 20 mM HEPES (pH 7.4) and seeded into the wells (5000-10,000 cells per well). Cells were allowed to attach for 2 h at 37°C in a 8% C 0 2 humid atmosphere. Non-adherent cells were removed by washing with 200 ju.1 DPBS per well until the cells in the BSA-coated control wells were sufficiently removed as monitored by visual inspection. Typically this took 3 washes. The attached cells were fixed with 3.8% phosphate buffered formalin and stained with 0.5% toluidine blue. Attached cells were counted directly or quantified by measurement o f the absorbance at 655 lini after solubilizing the cell bound toluidine blue in 100 jutl cetramide buffer (0.4% cetyltrimethylammoniumbromide, 0.1 M Tris(hydroxymethyl)aminometh ane (pH 8.5), 1 M NaCl). The num ber of cells was read from a calibration curve that was obtained by plotting the num ber o f cells as determined by directly counting against the absorbance measured.
Phorbol esters can stimulate integrm ligand-binding capacity ofintegrins, presumably by inducing conformational changes (Diamond and Springer, 1994) . In adhésion-stimulation assays, keratinocytes were, therefore, seeded in the presence of 25 nM phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich, Bornem, Belgium). In inhibition assays, antiserum was used to block the coated adhesive protein before seeding the cells by incubating coated wells with a saturating concentration of the appropriate antiserum in DPBS with 1 % BSA for 1.5 h at 37°C. AH assays were performed at least in duplicate, and in individual assays, triplicate or quadruplicate wells were used for each assay condition. Adhesion results were donor-independent as comparable results were obtained with keratinocytes of different individuals. secreted large amounts o f tenascin-C, as was reported previously (Erickson and Bourdon, 1989; Mackie and Tucker, 1992) , and of these, U138-M G was chosen as producer cell line for tenascin-C that was used in adhesion assays. Medium of dermal fibroblast cultures contained tenascin-C as well. Remarkably, tenascin-C was also detected in the m edium o f epidermal keratinocytes, cultured on a feeder layer o f irradiated mouse fibroblasts by the method of Rheinwald and Green or in the serum-free medium KGM. Western blot analysis o f tenascin-C in the supernatants of cultured kerati nocytes under reducing conditions revealed the presence of two immunoreactive bands w ith molecular weights greater than 200 kDa (data not shown). It should be noted that because of differences in cell num ber and m edium volume in the various cultures, the absolute amounts of tenascin-C produced cannot be compared directly.
RESULTS

T en a scin -C P r o d u c tio n b y C u ltu r e d C ells
T en a scin -C D e p o s itio n b y K eratinocytes C ultured on DED
W e used an in vitro model for reconstructed epidermis to investigate w hether tenascin-C is also produced in a culture model that allows full stratification of the keratinocytes and to analyze whether tenascin-C is deposited in the extracellular matrix or is only secreted in the medium. In this model keratinocytes are seeded on DED. The DED is prepared for culture in such a way that no viable cells remain in the tissue. This was confirmed by hematoxylin staining of DED, which demonstrated that no nuclei were present in the DED. Immuno his to chemical staining of DED with tenascin-C antiserum (T2H5, T N 2, A307, and TN953) was virtually negative. W h en keratinocytes were seeded on a layer of DED, however, marked tenascin-C staining was observed in the DED, indicating that the keratinocytes produce tenascin-C that is depos ited in the DED underneath. Tenascin-C was detected after 3 d of submerged culture, when the cultures resemble a squamous non keratinizing epithelium. Tenascin-C remained present at the der m al-epiderm al junction during subsequent air exposure, which induces terminal differentiation of the keratinocytes as indicated by the formation of a stratum corneum (Fig 1 ) .
K era tin o cy tes E xpress T en a scin -C during W o u n d H ealin g
In a previous study, w e described tenascin-C expression in healing wounds during a 14-d time course and its relationship with epidermal hyper-proliferation (Latijnhouwers et al, 1996) . W e now have extended the time course to 1 y, and instead of one polyclonal tenascin-C antiserum (i.e., A107), we have now used a panel of monoclonal antibodies and polyclonal antiserum in combination with a more sensitive staining protocol, which indicates that the expression levels of tenascin-C in healing skin wounds are much higher than previously anticipated. In addition to the known increase o f tenascin-C expression in the papillary dermis at the w ound margins, we noticed a thin discontinuous line of staining beneath migrated keratinocytes. Both with the polyclonal anti serum and the m onoclonal antibodies, deposition of tenascin-C in the w ound bed was observed beneath the entire sheet of migrating p * j. ,1
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f"a g serum-or feeder-derived factors are not necessary to induce tenascin-C production. Immunohistochemical analysis of reconstructed epidermis showed that keratinocytes in vitro are able to deposit tenascin-C in the extracellular matrix as well. Tenas c in -C was detected in cultures that were maintained submerged in air-exposed culture. W hether this is caused by continued tenas c in -C expression or cannot turnover of previously made protein tenascin-C in vivo. These in vitro models, the monolayer keratinocyte culture systems and the reconstructed epidermis, should be useful when further investigating the regulation and effects of epidermal tenascin-C expression. T he finding that keratinocytes express tenascin-C in vitro is clearly relevant for the in vivo situation, as we could detect tenascin-C in the epidermis of healing skin wounds at the protein and the m R N A levels. Epidermal tenascin-C expression was pre viously demonstrated in feeder-cultured human keratinocytes1 and in amphibian epidermis (Onda et al, 1991) . R ecently, Aukhil and colleagues (1996) reported on. tenascin-C expression by keratino cytes during healing of incisional wounds in rats where they observed expression patters similar to what we found in human tissue.. In a previous report we concluded that keratinocytes could interact with tenascin-C in the later stages o f wound healing but were unlikely to come into contact with tenascin-C in the early phase because of the undetectable levels of tenascin-C under the migrating keratinocytes (Latijnhouwers et al, 1996) , We, how ever, have now used a panel of polyclonal and monoclonal antibodies combined with a much more sensitive staining protocol .««MW 7 that indicates that the of C are much higher than previously anticipated. In this study we could detect tenascin-C in the dermis underneath the migrating keratinocytes. In addition, keratinocytes themselves are stained for tenascin-C pro tein. In situ hybridization results indicate that in the early phase of w ound healing, before wound closure, of the neo epidermis are the major source o f tenascin-C. By the time that the w ounds are closed, tenascin-C production in the neo-epidermis is . Figure 8 . A d h esio n o f fe e d e r -c u ltu r e d k Error bars, SEM [laminin (LN) and fibronectin (FN), n = 12 (without PMA) and n = 5 (with PMA), respectively; tenascin-C (TN), n = 12 in both conditions].
levels are reached later than m axim um m R N A levels and that the turnover of tenascin-C in the w ounds is rather slow.
Because tenascin-C is detected beneath the migrating keratino cytes that do not encounter an intact basal m em brane structure (Latijnhouwers c t al, 1996), we w ondered w hether it may function as a kind o f provisionary matrix to w hich these keratinocytes adhere. The results of the adhesion assays indicate that keratino cytes adhere poorly to tenascin-C. Therefore, tenascin-C does not seem to be an important adhesive substrate for keratinocytes. A prerequisite for tenascin-C having a direct effect on keratinocytes is interaction between kei-atinocytes and tenascin-C, w hich is most likely receptor-mediated. In the adhesion assays, very few kerati nocytes remained attached to tenascin-C, suggesting that interac tions between such putative receptors on kcratinocytes and tenas cin-C are not very strong. It should be noted, how ever, that strong intracellular effects may be evoked in spite o f weak receptor binding. This was recently reported for the interaction between fibronectin and a v integrins (Schwartz and Denninghoff, 1994) . Although fibronectin binding to these receptors is m uch weaker than binding to a 5j8t, the former interaction evokes the rise in intracellular Ca2H~ that was observed in cells that adhered to fibronectin.
Although tenascin-C does not m ediate strong keratinocyte ad hesion, it may well affect adhesion of keratinocytes to other proteins. It is known, for example, that tenascin-C inhibits fi bronectin adhesion of various cells (Lotz et al, 1989; Lightner and Erickson, 1990; Murphy Ullrich et al, 1991; Prieto et al, 1993) . Modulation of keratinocyte adhesion might be a m ajor function of tenascin-C in vivo. This may be especially im portant during wound healing, where keratinocytes have to migrate to close the wound. Tenascin-C might facilitate keratinocyte migration by weakening the adhesion to fibronectin and possibly other extracellular matrix proteins that could otherwise interfere w ith keratinocyte migration and subsequent wound closure. M odulation o f keratinocyte adhe sion by tenascin-C is likely to be receptor-m ediated. In the literature, various tenascin-C receptors have been described (Bour don and Ruoslahti, 1989; Salmivirta et al, 1991; Prieto et al, 1993; Sriramarao et al, 1993; Bamea et al, 1994; C hung and Erickson, 1994; Vaughan et. al, 1994; Yokosaki et al, 1994; V arnum Finney et al, 1995) , and of these, the a v/36 integrin is an interesting candidate. Keratinocytes normally do not express a vj36 but expression is induced in vitro after subculturing of keratinocytes and in vivo cev)36 is expressed by wound keratinocytes (Breuss et al, 1995; Haapasalmi et al, 1996) . The site o f G !vj36 expression, namely, the basal keratinocytes o f the neo-epidermis, and the level o f expres sion coincide with the site and level of tenascin-C expression. Receptors other than a vj36 could also bring about adhesion mod ulation by tenascin-C, such as the j3t integrins. Expression o f /3t integrins generally is strongly upregulated in wounds (Grinnell, 1992; Hertle et al, 1992; Laijava et al, 1993; W att and Jones, 1993) and various /3l integrins are able to bind tenascin-C (Bourdon and Ruoslahti, 1989; Prieto et al, 1993; Sriramarao et al, 1993; Yokosaki et al, 1994; Varnum Finney et al, 1995) . Among the non-integrintype tenascin-C receptors described, syndecan and annexin II could be important Chung and Erickson, 1994) .
The expression o f the membrane bound proteoglycan syndecan is altered during w ound healing in the epidermis and the granulation tissue, the sites where we found changes in tenascin-C expression as well Oksala et al, 1995) . Expression o f the glycoprotein annexin II during wound healing has not been studied, but annexin II is present on the surface of keratinocytes in vitro and in vivo in normal and pathologic conditions (Culard et al, 1992; Bastian et al, 1993; M a et al, 1994) . Moreover, recent findings of Chung et al (1996) support the idea that annexin II could have a major role in tenascin-C-mediated effects on cell migration. W e conclude that keratinocytes are a major source of tenascin-C in the early phase of normal human wound healing, and we hypothesize that tenascin-C may have an anti-adhesive effect on keratinocytes.
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